Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Miami, FL, Jan. 17, 2018 -- Biorasi, a leading full-service global CRO, is pleased to announce today the opening of their new Japanese office, located in Tokyo. This milestone marks Biorasi’s first regional headquarters located in East Asia, and dramatically expands Biorasi’s capabilities to manage trials in Japan and surrounding territories. The new office will become the command center for all East-Asian operations.
|
|||
“We had two major objectives with our Japanese office. The primary objective grew out of our sponsors’ needs for a Japanese component in increasingly complex studies. While a traditional CRO may have simply used a subcontractor, the challenging nature of modern drug trials requires direct management and optimization processes to succeed,” said Dr. Boris Reznik, Chairman of Biorasi. “But additionally, we recognize that Japan is a leader in healthcare innovation, and more than ever Western companies are reaching out to Japanese partners to accelerate the development of their breakthrough products. Opening a Japanese office allows us to better serve the future needs of our sponsors, and fits into our continuing mission to be the partner of choice for companies seeking global, optimized clinical development.”
Biorasi has conducted trials in Japan and other Asian countries for more than a decade through its global CRO partnership network, but the opening of the new corporate office in Japan represents a significant new commitment to supporting both the Asian domestic market and the American and European markets as they collaborate with Japanese pharmaceutical companies. The Tokyo office is the 6th regional headquarters Biorasi has opened, following Miami, Moscow, Kiev, Dusseldorf, and Mumbai. With growth remaining strong, however, the company looks forward to expanding even further in the near future.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e5888bc-e689-42f2-8246-a68e30507404
Alexandre Mouravskiy Biorasi 1.786.888.1822 [email protected]
